HUYA Bioscience International, a biopharmaceutical company with offices in the US, Japan and China, has expanded its senior management team, with the appointment of Yoshiki Shimamura as Vice President for Japan Operations.
Shimamura has more than 25 years of experience in the biopharma industry and clinical research organisations in Japan and South Korea, including companies such as Novocure, Hospira Japan, Chong Kun Dang Pharmaceutical Co, Amgen and Taiho Pharmaceutical Co.
HUYA's CEO Mireille Gillings said Shimamura's broad experience in clinical operations, business development and marketing will help the company advance candidate products in the Japanese market, where the company is making use of the Tripartite Health Cooperation between China, Korea and Japan.
The company aims to accelerate approval of its products in Japan based on Chinese clinical trials data.
